A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
Authors
Keywords
-
Journal
MOLECULES
Volume 26, Issue 23, Pages 7294
Publisher
MDPI AG
Online
2021-12-01
DOI
10.3390/molecules26237294
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trop2 deal heats up antibody–drug conjugate space in cancer
- (2021) Catherine Shaffer NATURE BIOTECHNOLOGY
- TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
- (2021) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
- (2021) Federica Martorana et al. Frontiers in Pharmacology
- Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
- (2021) A. Bardia et al. ANNALS OF ONCOLOGY
- 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
- (2021) S. Loibl et al. ANNALS OF ONCOLOGY
- 700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
- (2021) Y. Loriot et al. ANNALS OF ONCOLOGY
- 720TiP Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
- (2021) R.K. Jain et al. ANNALS OF ONCOLOGY
- PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
- (2021) Silvia Rita Vitale et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
- (2021) Shutan Liao et al. DRUG DEVELOPMENT RESEARCH
- Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
- (2021) Kamal S Saini et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities
- (2021) Laura M. Spring et al. ONCOLOGIST
- Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
- (2021) James T. Coates et al. Cancer Discovery
- Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer
- (2021) Emanuela Guerra et al. NEOPLASIA
- Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
- (2021) Timothee Olivier et al. Translational Oncology
- Case report of sacituzumab govitecan-hziy-induced neutropenia in a patient with metastatic triple-negative breast cancer and a uridine diphosphate glucuronosyltransferase family 1 member A1 poor metabolizer genotype
- (2021) Grace Baek et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
- (2021) Jigang Chen et al. Frontiers in Oncology
- Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
- (2020) Burak Zeybek et al. Scientific Reports
- Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
- (2020) David M. Goldenberg et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- Slug-expressing mouse prostate epithelial cells have increased stem cell potential
- (2020) Zuzana Kahounová et al. Stem Cell Research
- The emerging role of antibody-drug conjugates in urothelial carcinoma
- (2020) Michael Lattanzi et al. Expert Review of Anticancer Therapy
- 547P Rucaparib + sacituzumab govitecan (SG): Initial data from the phase Ib/II SEASTAR study (NCT03992131)
- (2020) T.A. Yap et al. ANNALS OF ONCOLOGY
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer
- (2020) John M. Seligson et al. ANNALS OF PHARMACOTHERAPY
- Antibody–Drug Conjugates for Cancer Therapy
- (2020) Umbreen Hafeez et al. MOLECULES
- The role and molecular mechanism of Trop2 induced epithelial-mesenchymal transition through mediated β-catenin in gastric cancer
- (2019) Wei Zhao et al. Cancer Medicine
- Targeting Trop-2 in solid tumors: future prospects
- (2019) Saif Zaman et al. OncoTargets and Therapy
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
- (2019) Jennifer Weiss et al. Expert Review of Anticancer Therapy
- Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo
- (2019) Emanuele Perrone et al. Molecular Oncology
- Trop2 is a potential biomarker for the promotion of EMT in human breast cancer
- (2018) Wei Zhao et al. ONCOLOGY REPORTS
- TNF-α promotes colon cancer cell migration and invasion by upregulating TROP-2
- (2018) Peng Zhao et al. Oncology Letters
- TROP2 promotes the proliferation and metastasis of glioblastoma cells by activating the JAK2/STAT3 signaling pathway
- (2018) Jianbing Hou et al. ONCOLOGY REPORTS
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT
- (2017) Xinxing Li et al. Oncotarget
- Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers
- (2016) C.-H. Chang et al. MOLECULAR CANCER THERAPEUTICS
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
- (2016) Ping Zeng et al. Scientific Reports
- Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
- (2015) Thomas M. Cardillo et al. BIOCONJUGATE CHEMISTRY
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
- (2015) R. M. Sharkey et al. CLINICAL CANCER RESEARCH
- Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
- (2015) David M. Goldenberg et al. Oncotarget
- Trop-2 Promotes Prostate Cancer Metastasis By Modulating 1 Integrin Functions
- (2013) M. Trerotola et al. CANCER RESEARCH
- Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis
- (2012) Marco Trerotola et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- High expression of TROP2 correlates with poor prognosis in pancreatic cancer
- (2008) D Fong et al. BRITISH JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started